Cytiva

Cytiva is a critical enabler in the global biopharmaceutical manufacturing ecosystem, providing essential tools and services that underpin the production of biologic drugs, including monoclonal antibodies, vaccines, and cell and gene therapies. As a former part of GE Healthcare Life Sciences, it operates as a standalone entity with a deep legacy in bioprocessing, positioned to capitalize on the rapid growth of the biologics market. The company's integrated offerings, from single-use technologies to enterprise-scale solutions and digital services, make it a key partner for both emerging biotechs and large pharmaceutical companies aiming to accelerate and de-risk their manufacturing processes.

Integrated suite of biopharmaceutical manufacturing technologies including cell culture systems, chromatography resins & systems, filtration products, single-use equipment, and associated software & services.

Cytiva operates in a highly competitive global market. Its primary competitors include Thermo Fisher Scientific (Life Technologies Solutions Group, Patheon), Merck KGaA (MilliporeSigma), Sartorius, and Repligen. Competition is based on technology performance, product portfolio breadth, price, service, and the ability to provide integrated, scalable solutions.